Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 18, 2009, Pages 6671-6681

  Ghirmai, Senait ^a   Azar, Marc R ^b,c   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b Behavioral Pharma Inc   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol cessation agents; Beta naltrexamides; In vitro in vivo studies; Metabolism

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' BROMO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' IODO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' METHYL)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' TERT BUTYL)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' TRIMETHYLFLUORO)BENZAMIDO]MORPHINAN; 6 NALTREXAMINE DERIVATIVE; ALCOHOL; AMIDE; AROMATIC CARBOXYLIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; FUNCTIONAL GROUP; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALTREXAMINE DERIVATIVE; NOCICEPTIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFUR 35; UNCLASSIFIED DRUG;

ALCOHOL ABSTINENCE; AMIDATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER; MALE; METABOLISM; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; HUMANS; LIVER; MALE; MICE; NALTREXONE; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 69249120307     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.07.069     Document Type: Article

References (40)

1. Bouza C., Angeles M., Munoz A., and Amate J.M. Addiction 99 (2004) 811
2. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., and Dias J.K. Am. J. Psychiatry 156 (1999) 1758
3. Croop R.S., Faulkner E.B., and Labriola D.F. Arch. Gen. Psychiatry 54 (1997) 1130
4. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., and Cutler R.B. Arch. Gen. Psychiatry 56 (1999) 719
5. Tabakoff B., and Hoffman P.L. Life Sci. 32 (1983) 197
6. Oslin D.W., Berrettini W.H., and O'Brien C.P. Addict. Biol. 11 (2006) 397
7. Roozen H.G., de Waart R., van der Windt D.A., van den Brink W., de Jong C.A., and Kerkhof A.J. Eur. Neuropsychopharmacol. 16 (2006) 311
8. Benjamin D., Grant E.R., and Pohorecky L.A. Brain Res. 621 (1993) 137
9. Stromberg M.F., Mackler S.A., Volpicelli J.R., and O'Brien C.P. Alcohol 23 (2001) 109
10. Pastor R., and Aragon C.M. Neuropsychopharmacology 31 (2006) 1489
11. Reid L.D. Am. J. Clin. Nutr. 42 (1985) 1099
12. Yeomans M.R., and Gray R.W. Neurosci. Biobehav. Rev. 26 (2002) 713
13. Grisel J.E., Grahame N.J., Mogil J.S., Belknap J.K., and Low M.J. Soc. Neurosci. Abstr. 21 (1995) 1699
14. Gianoulakis C., Krishnan B., and Thavundayil J. Arch. Gen. Psychiatry 53 (1996) 250
15. Herz A. Psychopharmacology (Berl) 129 (1997) 99
16. Ulm R.R., Volpicelli J.R., and Volpicelli L.A. J. Clin. Psychiatry 56 (1995) 5
17. Li G., Aschenbach L.C., Chen J., Cassidy M.P., Stevens D.L., Gabra B.H., Selley D.E., Dewey W.L., Westkaemper R.B., and Zhang Y. J. Med. Chem. 52 (2009) 1416
18. Ghirmai S., Azar M.R., Polgar W.E., Berzetei-Gurske I., and Cashman J.R. J. Med. Chem. 51 (2008) 1913
19. Mohamed M.S., and Portoghese P.S. J. Org. Chem. 51 (1986) 105
20. Traynor J.R., and Nahorski S.R. Mol. Pharmacol. 47 (1995) 848
21. Tullman R.H., and Hanzlik R.P. Drug Metab. Rev. 15 (1984) 1163
22. Bondon A., Macdonald T.L., Harris T.M., and Guengerich F.P. J. Biol. Chem. 264 (1989) 1988
23. Denton T.T., Zhang X., and Cashman J.R. Biochem. Pharmacol. 67 (2004) 751
24. MacDougall J.M., Zhang X.D., Polgar W.E., Khroyan T.V., Toll L., and Cashman J.R. J. Med. Chem. 47 (2004) 5809
25. Heyser C.J., Schulteis G., and Koob G.F. Alcohol Clin. Exp. Res. 21 (1997) 784
26. Heyser C.J., Roberts A.J., Schulteis G., and Koob G.F. Alcohol Clin. Exp. Res. 23 (1999) 1468
27. Heyser C.J., Moc K., and Koob G.F. Neuropsychopharmacology 28 (2003) 1463
28. June H.L., Grey C., Warren-Reese C., Durr L.F., Ricks-Cord A., Johnson A., McCane S., Williams L.S., Mason D., Cummings R., and Lawrence A. Alcohol Clin. Exp. Res. 22 (1998) 2174
29. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., and Gold L.H. J. Pharmacol. Exp. Ther. 293 (2000) 1002
30. Holter S.M., and Spanagel R. Psychopharmacology (Berl) 145 (1999) 360
31. Walker B.M., and Koob G.F. Neuropsychopharmacology 33 (2008) 643
32. Lowry T.H., and Richardson K.S. Mechanism and Theory in Organic Chemistry. 3rd ed. (1987), Harper and Row, New York
33. Cashman J.R., and MacDougall J.M. Curr. Top. Med. Chem. 5 (2005) 585
34. Stevens Jr. W.C., Jones R.M., Subramanian G., Metzger T.G., Ferguson D.M., and Portoghese P.S. J. Med. Chem. 43 (2000) 2759
35. Doss G.A., and Baillie T.A. Drug Metab. Rev. 38 (2006) 641
36. Brunelle A., Bi Y.A., Lin J., Russell B., Luy L., Berkman C., and Cashman J. Drug Metab. Dispos. 25 (1997) 1001
37. Roth B.L., Laskowski M.B., and Coscia C.J. J. Biol. Chem. 256 (1981) 10017
38. Yano J.K., Denton T.T., Cerny M.A., Zhang X., Johnson E.F., and Cashman J.R. J. Med. Chem. 49 (2006) 6987
39. Rassnick S., Pulvirenti L., and Koob G.F. Alcohol 10 (1993) 127
40. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099